Imunon (NASDAQ:IMNN) said its pivotal Phase III OVATION 3 trial in newly diagnosed advanced ovarian cancer is progressing on track, as management highlighted final Phase II OVATION 2 data and outlined a financing approach intended to support the study while limiting dilution.
On the company’s first-quarter 2026 earnings call, President and Chief Executive Officer Dr. Stacy Lindborg said Imunon entered the second quarter with “continued momentum” after what she described as a transformative 2025. The company recently announced final clinical data from the completed OVATION 2 Phase II study of its proprietary IL-12 immunotherapy, referred to on the call as IMNN-001 and as part of the IMNN-101 program.
OVATION 2 Data Supports Phase III Push
Faller said the gynecologic oncology community’s enthusiasm for the program continues to grow, citing Phase II OVATION 2 clinical data showing a 14.7-month median overall survival benefit for IMNN-001 plus standard-of-care chemotherapy. He also said the treatment demonstrated activation of both innate and adaptive immunity.
Faller described the therapy’s profile as involving localized IL-12 delivery with “negligible systemic exposure,” favorable safety and signs of immune activation that he said were predictive of better outcomes. The company expects to present final overall survival results from OVATION 2 at an upcoming national conference.
Management also said Imunon plans to hold an R&D Day in the third quarter of 2026. Faller said the event will include the final efficacy analysis from OVATION 2, additional safety, efficacy and translational data from the company’s MRD study, and further translational data from OVATION 2.
Enrollment and Trial Design
During the call, analysts focused heavily on OVATION 3 enrollment. Lindborg said the company has been ahead of internal monthly enrollment forecasts and is increasing the number of activated clinical sites. She said early sites, including strong partners from OVATION 2, have performed well and that some sites are above Imunon’s assumptions for patient enrollment per site.
Faller said investigators have been proactively approaching Imunon about joining OVATION 3, and he described site engagement as strong. He said some sites have shown “a flurry of activity” shortly after activation, which he attributed to investigators’ belief in the potential benefit of IMNN-001.
Lindborg said OVATION 3 is unblinded for patients and treating clinicians because inserting a catheter in control-arm patients would be unethical, a position she said the FDA agreed with. She added that Imunon will internally protect trial integrity by limiting access to data unless needed. The trial is designed with two interim analyses that could allow early stopping for efficacy, with the first expected about one to one-and-a-half years after full enrollment and the second about a year later, according to Lindborg.
Asked about the changing ovarian cancer treatment landscape, including WEE1 inhibitors, antibody-drug conjugates and PI3K-related approaches, Faller said he is encouraged by development in later-line therapies but characterized the benefits to date as modest. He said the company’s study is focused on frontline treatment, where Imunon aims to reproduce the more than one-year survival benefit seen in OVATION 2.
Financing Strategy and Cash Discipline
Lindborg acknowledged that the capital funding environment remains challenging for Imunon and the biotechnology sector more broadly. She said the company is sharpening its focus on OVATION 3 enrollment and conserving cash.
The company is pursuing what Lindborg called a “disciplined bridge financing strategy” designed to raise targeted capital for OVATION 3 while bringing Imunon closer to trial readouts. She said potential financing structures could include preferred shares that are not immediately tradable, do not include warrants, and would increase shareholder equity. Lindborg contrasted that approach with registered direct offerings, which she said are typically dilutive and may involve investors with little long-term interest in the company.
Lindborg also said Imunon is confident its clinical data can attract investment from one or more strategic partners in a minimally dilutive or non-dilutive manner. She said shareholder value remains a central consideration as the company seeks to fund OVATION 3.
First-Quarter Financial Results
Interim Chief Financial Officer Jeffrey Church said Imunon’s first-quarter financial results were included in the company’s press release and Form 10-Q filed before the market opened.
- Research and development expenses rose to $2.3 million in the first quarter of 2026 from $2.2 million in the prior-year period.
- General and administrative expenses were unchanged at $2.2 million in both the first quarter of 2026 and the first quarter of 2025.
- Net cash used in operating activities was $4.0 million in the first quarter, compared with $2.8 million a year earlier.
Church said the increase in operating cash use was largely due to trial-related expenses tied to starting OVATION 3. He said Imunon continues to manage its cash position through targeted financing activities, cost-saving initiatives and operational efficiencies.
In response to an analyst question, Church said the company expects quarterly spending in the coming periods to be in the range of $4.5 million to $5.0 million. He said G&A expenses are expected to remain fairly consistent with first-quarter levels, while spending may rise as more sites are added and OVATION 3 enrollment increases.
Lindborg said the company’s recent restructuring included eliminated positions and redefined roles, with resources focused on the Phase III trial, manufacturing, preparation for a potential biologics license application, and the longer-term commercial landscape.
Regulatory Focus Remains on Overall Survival
Management said Imunon is focused on full approval rather than accelerated approval. Lindborg said the trial was designed with FDA engagement and that interim analyses are part of the agreed trial design and analysis plan.
Faller added that accelerated approvals are typically based on surrogate endpoints, while Imunon’s Phase III study uses overall survival as its primary endpoint. He said FDA guidance in oncology continues to support overall survival as the “gold standard.”
In closing remarks, Lindborg said Imunon remains focused on OVATION 3 enrollment, the strength of Phase II overall survival data, translational evidence and financial discipline as it seeks to advance its ovarian cancer program.
About Imunon (NASDAQ:IMNN)
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.
